GlycoMimetics (NASDAQ:GLYC) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.31) by 9.68 percent. This is a 12.5 percent increase over losses of $(0.32) per share from the same period last year.
Wells Fargo Maintains Underweight on Aptiv, Lowers Price Target to $112
Wells Fargo analyst Colin Langan maintains Aptiv (NYSE:APTV) with a Underweight and lowers the price target from $124 to $112.